Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ALKS - Alkermes plc
Market Cap 4.64B P/E - EPS this Y 87.50% Ern Qtrly Grth -61.50%
Income 385.71M Forward P/E 13.12 EPS next Y -3.00% 50D Avg Chg -9.00%
Sales 1.51B PEG 0.41 EPS past 5Y 25.67% 200D Avg Chg 1.00%
Dividend N/A Price/Book 3.63 EPS next 5Y 24.80% 52W High Chg -17.00%
Recommedations 2.40 Quick Ratio 2.42 Shares Outstanding 164.67M 52W Low Chg 29.00%
Insider Own 1.31% ROA 8.62% Shares Float 156.26M Beta 0.42
Inst Own 112.37% ROE 30.08% Shares Shorted/Prior 18.62M/17.70M Price 27.95
Gross Margin 83.31% Profit Margin 19.15% Avg. Volume 1,405,774 Target Price 34.92
Oper. Margin 27.53% Earnings Date Jul 24 Volume 2,776,204 Change -2.07%
Healthcare | Drug Manufacturers - Specialty & Generic | Ireland
About Alkermes plc

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes plc News
12/20/24 The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
12/06/24 Qiagen (QGEN) Down 1.6% Since Last Earnings Report: Can It Rebound?
12/05/24 Ultragenyx (RARE) Down 6.8% Since Last Earnings Report: Can It Rebound?
12/04/24 Illumina (ILMN) Down 9.3% Since Last Earnings Report: Can It Rebound?
11/29/24 Glaxo (GSK) Down 6.6% Since Last Earnings Report: Can It Rebound?
11/28/24 Why Is Incyte (INCY) Up 2.1% Since Last Earnings Report?
11/26/24 Axsome Therapeutics eyes approval after Phase III narcolepsy win
11/25/24 Alkermes to Participate in Upcoming Investor Conferences
11/21/24 Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock?
11/11/24 Alkermes to Participate in Two Upcoming Investor Conferences
11/07/24 Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences
10/25/24 Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
10/25/24 Alkermes Third Quarter 2024 Earnings: EPS Misses Expectations
10/25/24 Alkermes PLC (ALKS) Q3 2024 Earnings Call Highlights: Strong Proprietary Product Growth and ...
10/24/24 Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
10/24/24 Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates
10/24/24 Alkermes: Q3 Earnings Snapshot
10/24/24 Alkermes plc Reports Third Quarter 2024 Financial Results
10/22/24 BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
10/22/24 Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
LAURENCIN CATO T Director Director Jun 07 Sell 31.5 2,800 88,200 7,479 06/07/23
LAURENCIN CATO T Director Director Jun 07 Option 22.97 2,800 64,316 10,279 06/07/23
Nichols Christian Todd SVP, Chief Commercia.. SVP, Chief Commercial Officer May 30 Sell 28.93 27,134 784,987 40,984 05/30/23
Nichols Christian Todd SVP, Chief Commercia.. SVP, Chief Commercial Officer May 30 Option 20.43 19,634 401,123 68,118 05/30/23
Nichols Christian Todd SVP, Chief Commercia.. SVP, Chief Commercial Officer Jun 21 Sell 28.2584 7,474 211,203 21,035 06/21/22
POPS RICHARD F Director and CEO, Al.. Director and CEO, Alkermes plc May 05 Option 16.55 450,000 7,447,500 1,062,046 05/06/22
POPS RICHARD F Director and CEO, Al.. Director and CEO, Alkermes plc May 05 Sell 28.13 347,257 9,768,339 968,299 05/06/22
Cooke Shane Director Director Apr 11 Option 16.55 10,000 165,500 100,478 04/12/22
Cooke Shane Director Director Apr 11 Sell 29.26 10,000 292,600 90,478 04/12/22
Cooke Shane Director Director Apr 04 Option 16.55 10,000 165,500 100,478 04/05/22
Cooke Shane Director Director Apr 04 Sell 28.18 10,000 281,800 90,478 04/05/22
Hopkinson Craig C. EVP R&D, Chief Medic.. EVP R&D, Chief Medical Officer Feb 23 Sell 24.7559 11,983 296,650 17,994 02/24/22
Hopkinson Craig C. EVP R&D, Chief Medic.. EVP R&D, Chief Medical Officer Feb 18 Sell 25.17 2,306 58,042 9,496 02/23/22
ANSTICE DAVID W Director Director Jun 08 Option 14.6 5,000 73,000 78,081 06/08/21
DIXON WENDY L Director Director Apr 20 Option 14.6 25,000 365,000 61,600 04/20/21
DIXON WENDY L Director Director Apr 20 Sell 20 25,000 500,000 36,600 04/20/21
Brown Iain Michael SVP, Chief Financial.. SVP, Chief Financial Officer Apr 20 Option 18.11 35,000 633,850 83,154 04/20/21
Brown Iain Michael SVP, Chief Financial.. SVP, Chief Financial Officer Apr 20 Sell 19.99 35,000 699,650 48,362 04/20/21
DIXON WENDY L Director Director Jan 15 Option 12.62 35,000 441,700 36,600 01/15/21